Hakan Harputluoğlu

9.5k total citations
49 papers, 728 citations indexed

About

Hakan Harputluoğlu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Hakan Harputluoğlu has authored 49 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Hakan Harputluoğlu's work include HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Hakan Harputluoğlu is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Cancer Treatment and Pharmacology (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Hakan Harputluoğlu collaborates with scholars based in Türkiye, United States and Italy. Hakan Harputluoğlu's co-authors include Sercan Aksoy, Ömer Dızdar, Kadri Altundağ, Saadettin Kılıçkap, Didem Şener Dede, İbrahim Barışta, Mutlu Hayran, Mustafa Erman, Yavuz Özışık and Fevziye Ünsal Malas and has published in prestigious journals such as Journal of Clinical Oncology, The FASEB Journal and Annals of Oncology.

In The Last Decade

Hakan Harputluoğlu

44 papers receiving 715 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Hakan Harputluoğlu 364 168 131 127 125 49 728
Berksoy Şahin 322 0.9× 109 0.6× 99 0.8× 169 1.3× 177 1.4× 59 840
Lydia Gedmintas 595 1.6× 217 1.3× 149 1.1× 108 0.9× 89 0.7× 16 894
Jean Tayar 453 1.2× 138 0.8× 185 1.4× 93 0.7× 137 1.1× 30 846
Akio Kohno 264 0.7× 119 0.7× 135 1.0× 61 0.5× 96 0.8× 63 770
Ami V. Desai 250 0.7× 229 1.4× 94 0.7× 185 1.5× 111 0.9× 52 1.0k
Walter Longo 387 1.1× 121 0.7× 154 1.2× 59 0.5× 254 2.0× 62 843
Felix Keil 299 0.8× 104 0.6× 158 1.2× 72 0.6× 115 0.9× 81 1.1k
Jeffrey Margolis 307 0.8× 227 1.4× 154 1.2× 62 0.5× 140 1.1× 35 1.1k
Nicola Piccirillo 176 0.5× 66 0.4× 184 1.4× 59 0.5× 94 0.8× 67 715
T. Economopoulos 294 0.8× 114 0.7× 61 0.5× 51 0.4× 203 1.6× 32 694

Countries citing papers authored by Hakan Harputluoğlu

Since Specialization
Citations

This map shows the geographic impact of Hakan Harputluoğlu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hakan Harputluoğlu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hakan Harputluoğlu more than expected).

Fields of papers citing papers by Hakan Harputluoğlu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hakan Harputluoğlu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hakan Harputluoğlu. The network helps show where Hakan Harputluoğlu may publish in the future.

Co-authorship network of co-authors of Hakan Harputluoğlu

This figure shows the co-authorship network connecting the top 25 collaborators of Hakan Harputluoğlu. A scholar is included among the top collaborators of Hakan Harputluoğlu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hakan Harputluoğlu. Hakan Harputluoğlu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Solomon, Benjamin, Yi‐Long Wu, Rafał Dziadziuszko, et al.. (2024). 1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo). Annals of Oncology. 35. S775–S775. 1 indexed citations
3.
Harputluoğlu, Hakan, et al.. (2022). Advanced Hepatocellular Cancer Treated with Sorafenib and Novel Inflammatory Markers. Journal of Gastrointestinal Cancer. 54(1). 11–19. 4 indexed citations
4.
5.
Budakoğlu, Burçin, Kadri Altundağ, Sercan Aksoy, et al.. (2018). Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.. PubMed. 19(4). 872–8. 3 indexed citations
6.
Bilgiç, Yılmaz, Hakan Harputluoğlu, Neşe Karadağ, et al.. (2017). Drug induced autoimmune hepatitis: a single center experience. Biomedical Research-tokyo. 28(15). 6528–6532.
7.
Bilgiç, Yılmaz, Yasir Furkan Çağın, Oğuzhan Yıldırım, et al.. (2017). Does the tumor necrosis factor a predictor factor in patients with chronic hepatitis B and C. Biomedical Research-tokyo. 28(4). 1683–1688. 1 indexed citations
8.
Arslan, Ahmet Kadir, et al.. (2016). Estimation of risk factors associated with colorectal cancer: an application of knowledge discovery in databases. Kuwait Journal of Science. 43(2). 6 indexed citations
9.
Demırcı, Umut, Bilge Aktaş, Ahmet Alacacıoğlu, et al.. (2013). Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Journal of Cancer Research and Clinical Oncology. 139(5). 829–835. 7 indexed citations
10.
Kefeli, Umut, Mustafa Beneklı, Alper Sevinç, et al.. (2013). Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience. Oncology Letters. 6(2). 605–611. 9 indexed citations
11.
12.
Elkıran, Emin Tamer, Kaplan Ma, Alper Sevinç, et al.. (2012). Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Medical Oncology. 29(5). 3147–3154. 9 indexed citations
13.
Aktürk, Erdal, et al.. (2011). Kanser ilaçlarının kardiyovasküler yan etkileri: bu yan etkiler nasıl belirlenmeli, tedavi ve takip nasıl yapılmalı?. DergiPark (Istanbul University). 18(2). 1 indexed citations
14.
Arslan, Ülkü Yalçıntaş, Berna Öksüzoğlu, Sercan Aksoy, et al.. (2011). Breast cancer subtypes and outcomes of central nervous system metastases. The Breast. 20(6). 562–567. 43 indexed citations
15.
Arslan, Çağatay, Sercan Aksoy, Ömer Dızdar, et al.. (2010). Zoledronic acid and atrial fibrillation in cancer patients. Supportive Care in Cancer. 19(3). 425–430. 23 indexed citations
16.
Dızdar, Ömer, Ümit Tapan, Sercan Aksoy, et al.. (2008). Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. European Journal Of Haematology. 80(5). 381–385. 18 indexed citations
17.
Kılıçkap, Saadettin, Bünyamin Yavuz, Sercan Aksoy, et al.. (2008). Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma. Medical Oncology. 25(4). 437–442. 25 indexed citations
18.
Dızdar, Ömer, Mustafa Erman, Mustafa Cankurtaran, et al.. (2007). Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance. Annals of Hematology. 87(1). 57–60. 7 indexed citations
19.
Dinçer, Murat, et al.. (2006). Statins may decrease skeletal-related events in breast cancer patients with bone metastases. Medical Hypotheses. 67(5). 1146–1147. 3 indexed citations
20.
Aksoy, Sercan, et al.. (2006). Treatment of comorbidities besides the treatment of primary tumor may further increase effective management of cancer. Medical Hypotheses. 67(4). 744–746. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Berksoy Şahin Breakdown of academic impact, for papers by Lydia Gedmintas Breakdown of academic impact, for papers by Jean Tayar Breakdown of academic impact, for papers by Akio Kohno Breakdown of academic impact, for papers by Ami V. Desai Breakdown of academic impact, for papers by Walter Longo Breakdown of academic impact, for papers by Felix Keil Breakdown of academic impact, for papers by Jeffrey Margolis Breakdown of academic impact, for papers by Nicola Piccirillo Breakdown of academic impact, for papers by T. Economopoulos
Rankless by CCL
2026